lasofoxifene
Jump to navigation
Jump to search
Introduction
Manufacturer is seeking FDA approval Feb 2010.
Indications
- osteoporosis
- may lower risk for
- estrogen-receptor positive breast cancer (HR, 0.19)
- coronary heart disease events (HR, 0.68)
- stroke (HR, 0.64)
Dosage
- 0.25 mg or 0.5 mg P QD
Adverse effects
- venous thromboembolic events (HR, 2)
- pulmonary embolism (HR, > 4)
- endometrial polyps & hypertrophy
More general terms
References
- ↑ Cummings SR et al Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010 Feb 25; 362:686. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20181970
Becker C. Another selective estrogen-receptor modulator for osteoporosis. N Engl J Med 2010 Feb 25; 362:752 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20181977